A Phase I Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 06 Jan 2018
At a glance
- Drugs Cyclophosphamide (Primary) ; Dasatinib (Primary) ; Temsirolimus (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 17 Oct 2017 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 17 Oct 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
- 08 Oct 2015 Planned primary completion date changed from 1 Jun 2018 to 1 Oct 2018, as reported by ClinicalTrials.gov.